Yohimbex

Quick links to important sections

Yohimbex

Method of action: Urologicals

Treatment option: Impotence

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Yohimbex

Property Description
Active ingredient Yohimbine Hydrochloride
Form Oral Solid (Tablet or Capsule)
Pharmacological class alpha2-Adrenergic Receptor Antagonist
General purpose Tonic and Stimulant
Origin Derived from Pausinystalia yohimbe bark

Identity and Origin: Yohimbine as a Monoterpenoid Alkaloid

Yohimbex is defined as a commercial preparation containing the active constituent Yohimbine Hydrochloride, which is the purified salt form of a naturally derived monoterpenoid indole alkaloid. This compound originates historically from the bark of the West African tree, Pausinystalia yohimbe. While the plant source provides the natural alkaloid, Yohimbex specifically provides the highly purified or synthetic Yohimbine Hydrochloride (C21H26N2O3 cdot HCl) stabilized within an oral solid dosage form. This choice of a purified salt, rather than a crude extract, is consistent with pharmacological standards aimed at ensuring product consistency.


Yohimbine's Pharmacological Class and General Purpose

The active ingredient in Yohimbex is classified pharmacologically as a selective alpha2-adrenergic receptor antagonist, functionally categorized as a sympatholytic. This classification is the cornerstone of its identity, which has been the subject of numerous pharmacological studies, confirming its specific mechanism of action. The product is designed for oral administration and is supplied as a tablet or capsule, primarily positioned for use by the adult male patient group. The preparation is used as a single active ingredient product to address issues related to diminished physiological function.

The physiological action involves blocking specific nerve receptors, which subsequently promotes local vasodilation and increased sympathetic nervous system activity. This effect is clinically recognized for supporting localized circulation, which underpins its general purpose as a tonic and stimulant.

What side effects are possible with Yohimbex?

Possible Side Effects and Safety Information

The safety profile for Yohimbine Hydrochloride (the active ingredient in Yohimbex) is defined by its effect on the sympathetic nervous system, as documented by governmental regulatory authorities.

Adverse reactions are primarily categorized by their impact on the nervous and cardiovascular systems, consistent with its classification as an alpha-2 adrenergic receptor antagonist.


Officially Documented Adverse Reactions

System-Organ Class Commonly Reported Effects
Nervous System Disorders Anxiety, nervousness, tremor, headache, dizziness
Cardiovascular/Vascular Tachycardia (fast heartbeat), palpitations, elevated blood pressure, flushing
Gastrointestinal Disorders Nausea, vomiting, stomach upset

Serious Adverse Reactions and Restrictions

Although generally uncommon, the regulatory safety profile documents potential serious adverse reactions, including hypertensive crisis (severe elevated blood pressure), tachyarrhythmias (serious, rapid heart rhythms), and seizures.

Use of Yohimbex is formally contraindicated in individuals with certain pre-existing conditions. These safety-related restrictions include a ban on use in patients with severe cardiovascular disease (such as angina pectoris), severe renal impairment (kidney function issues), and severe hepatic impairment (liver function issues). These contraindications are in place to mitigate the risks associated with the medicine’s sympathetic effects. Safety advice also highlights caution for older adults who may have increased sensitivity to cardiovascular effects.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Yohimbex (Yohimbine Hydrochloride) overdose documents manifestations primarily consistent with excessive sympathomimetic activity. Documented clinical signs may include anxiety, tremors, diaphoresis (sweating), nausea, and tachycardia (rapid heart rate), often accompanied by fluctuating blood pressure, including both hypertension and hypotension.

Overdose is classified as potentially severe and life-threatening due to documented acute neurological and cardiovascular sequelae. These serious outcomes may involve seizures (particularly with higher doses), progression to coma or paralysis, cardiac collapse, and sudden death.


Required Emergency Action and Management

Regulatory guidance explicitly mandates that in all cases of suspected overdose, an individual must seek medical attention immediately and contact Poison Control. This immediate action is critical due to the rapid onset and severity of potential complications.

Treatment is defined as symptomatic and supportive care, as no specific antidote is known for Yohimbine intoxication. Continuous monitoring for severe symptoms is necessary. The official profile notes potential increased risk of toxicity in patients with underlying hepatic or renal dysfunction.

Therapeutic Uses of Yohimbex

The purified medication, Yohimbex (Yohimbine Hydrochloride), is relevant in contexts marked by increased discomfort or tension across several specific therapeutic domains. The purified form is historically relevant in the therapeutic domain of Erectile Dysfunction, and it is applicable in clinical settings where additional symptomatic support is needed.

The relevant therapeutic domains include Impaired Erectile Response, Orthostatic Hypotension in patients with Autonomic Failure, and diminished sexual function occurring as a side effect of certain long-term medications. Yohimbex is used to help with symptoms related to physical discomfort and systemic imbalance, contributing to overall comfort during symptomatic phases.

“This medication is commonly used to help with symptoms related to heightened physiological activity and conditions where functional stability becomes affected.”

For patients experiencing Impaired Erectile Response, this application may support the maintenance of functional stability, while for those dealing with Orthostatic Hypotension, it provides supportive relief that may assist with maintaining blood pressure during changes in posture. This may offer supportive therapeutic benefit for symptoms related to diminished function and helps ease the overall symptom burden associated with treatment-related sexual deficits.

Quick Fact: Relief for Orthostatic Intolerance
Yohimbex is applied in contexts involving heightened systemic burden to address symptoms related to systemic imbalance that may interfere with functional stability.

Regulatory References

  1. Yohimbine - LiverTox - NCBI Bookshelf - NIH

Eligibility and Restrictions for Use

Who Can and Cannot Use Yohimbex? (Official Regulatory Information)

Official regulatory guidelines strictly define the eligible patient population for Yohimbex (Yohimbine). The use of this medication is reserved for adults and is prohibited under several circumstances and for specific physiological states.

Absolute Contraindications

Yohimbex must not be used by individuals with the following conditions, as stated in authoritative government labeling:

  • Severe Organ Impairment: Severe renal dysfunction (kidney disease) or hepatic dysfunction (liver disease).
  • Cardiovascular Conditions: Uncontrolled hypertension (high blood pressure) or pre-existing heart disease (including angina pectoris).
  • Specific Clinical States: A history of peptic ulcer disease.
  • Hypersensitivity: Known allergy or hypersensitivity to the drug or its components.
  • Drug Interactions: Concurrent use with certain Monoamine Oxidase Inhibitors (MAOIs).

Special Population Restrictions

Population Group Regulatory Status
Pregnancy Contraindicated (Must not be used).
Breastfeeding Contraindicated (Must not be used).
Pediatric (Children/Adolescents) Use Not Established (Safety and efficacy data are lacking).
Psychiatric Illness Use requires extreme caution due to potential for exacerbation of symptoms (e.g., anxiety or depression).

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the clinically significant interactions of Yohimbex, as documented in authoritative regulatory and pharmacopoeial sources. These interactions are categorized by their nature and the resulting clinical implication.

High-Risk Pharmacodynamic Interactions

Co-administration with medicines that affect the sympathetic nervous system or central nervous system (CNS) activity may lead to additive or antagonistic effects. These high-risk combinations include:

  • Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs): Use with these classes is restricted due to the high potential for additive pressor effects or increased CNS stimulation, which can lead to hypertensive crisis.
  • Stimulant Drugs: Combination with amphetamines and related stimulants is restricted due to the elevated risk of significant increases in heart rate and blood pressure.

Pharmacokinetic and Antagonistic Effects

  • Antihypertensive Drugs: Yohimbex is documented to act as an alpha2-adrenergic antagonist, which can oppose the action of antihypertensive agents (e.g., Clonidine, beta-blockers), potentially reducing their intended therapeutic effect and requiring close monitoring.
  • CYP Enzyme Substrates: The product has the potential to alter the metabolic clearance of co-administered medicines that are substrates of CYP2D6, CYP3A4, or CYP1A2 enzymes, which may necessitate adjustments to the concomitant medicine.

Non-Medicinal Interactions

  • Tyramine-Rich Foods: Consumption of foods containing high levels of tyramine (e.g., aged cheeses, liver) is advised against, as this can increase the risk of hypertensive episodes when combined with the product.
  • Anticoagulant/Antiplatelet Agents: Co-use with agents that slow blood clotting is associated with an increased risk of bleeding and may require management. It is also advised to stop using the product at least two weeks before any scheduled surgery.

Mechanism of Action

The mechanism of Yohimbine Hydrochloride is defined by its competitive antagonism of the pre-synaptic Alpha-2 Adrenergic Receptors (alpha2-AR). These receptors act as an inhibitory negative feedback loop on nerve terminals, monitoring and limiting the release of the neurotransmitter Norepinephrine (NE). By blocking this 'brake,' Yohimbine removes the inhibition, leading to a marked and sustained increase in NE spillover in the central and peripheral nervous systems. The resulting surge of Norepinephrine activates the Sympathetic Nervous System (SNS), causing physiological consequences such as an elevated heart rate, a rise in systemic blood pressure, and enhanced central arousal and alertness via off-target modulation of dopamine and serotonin pathways. This mechanism also influences vascular smooth muscle tone, facilitating a relative localized increase in blood flow within specific vascular territories due to alpha2-antagonism and facilitated Nitric Oxide (NO) release, despite high systemic sympathetic tone. The non-selective affinity for secondary receptors introduces competing signaling that modulates the outcome of the primary alpha2-antagonism.

Dosage and Administration Information

How to Use Yohimbex: Official Administration Guidelines

The administration of Yohimbine Hydrochloride (Yohimbex) is defined by a set of instructions that establish a standardized approach to its use. The core usage principle is based on a divided daily dose of the oral solid form, administered multiple times throughout the day.


Administration Scope

Feature Guideline
Route of administration Oral administration using a solid dosage form (tablet or capsule).
Dosing schedule The standard adult dose is 5.4 mg taken per administration.
Frequency Dosing is administered in a divided dose pattern, specifically three times a day (TID).
Titration The regimen allows for an initial dose reduction to 2.7 mg if difficulties arise, with the intent of gradually returning to the standard 5.4 mg dose.
Contextual Use Duration The medication is intended for an intermittent or short-term course of use, often for periods not exceeding 10 weeks.

Procedural Rules and Population Constraints

Missed Dose Guidance: If a dose is missed, it should be taken as soon as possible unless it is near the time for the next scheduled dose, in which case the missed dose must be skipped. Patients are instructed not to double doses to compensate.

Population Constraints: Use of Yohimbine Hydrochloride is generally not established in pediatric patients (less than 18 years of age) and is also not recommended in geriatric patients. Specific precautions advise against use in patients with certain conditions, such as renal disease.


The use protocol is structured around the principle of a divided daily dose of the oral solid form. This regimen incorporates rules for gradual titration to manage patient adjustment and outlines instructions for handling missed doses without compensation. These principles define the standardized approach to the practical use of the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies for Yohimbex


Evidence for use in Impaired Erectile Response

Research has primarily explored the use of Yohimbine Hydrochloride in research contexts involving impaired erectile response, or erectile dysfunction (ED). The most relevant evidence is derived from systematic reviews and meta-analyses that pool data from short-term randomized controlled trials (RCTs). These studies were generally double-blind and placebo-controlled. Researchers have examined how the medicine was observed to affect adult male patients presenting with various forms of ED. Studies monitored outcomes related to physical discomfort and daily functioning. Findings describe patterns observed in erectile function when compared to the placebo group. However, follow-up durations were limited, typically lasting only 4 to 10 weeks, and long-term effects are not fully established.

Evidence for use in Orthostatic Hypotension

Research examined the use of Yohimbine Hydrochloride in research contexts involving patients experiencing Orthostatic Hypotension (low blood pressure upon standing) related to severe Autonomic Failure. This research relies on highly specific randomized, placebo-controlled, crossover trials. These studies research examined how the compound was observed in temporary physiological imbalance in patients whose symptoms are episodic or acute changes. Studies monitored outcomes related to systemic or functional imbalance, such as the change in diastolic blood pressure (DBP) upon standing. However, the evidence primarily focuses on acute administration, meaning data are insufficient regarding how the compound may be associated with long-term management.

Evidence for use in Diminished Sexual Function (Medication-Induced)

Research was evaluated in settings involving adults who were observed with a diminished sexual function that was associated with taking certain other long-term medications. The evidence is limited, referencing authoritative overviews and historical controlled studies. The research examined short-term symptom changes in studies focusing on episodes where symptoms become more noticeable. Initial findings indicate patterns related to outcomes related to systemic or functional imbalance within the studied groups. The certainty remains low, as there is limited information for long-term outcomes and sample sizes were modest in the foundational studies.

Key Uncertainties and Research Gaps

A key uncertainty is that the evidence quality varies across studies, and findings were mixed in some meta-analyses. The sample sizes were modest in many trials, which limits the ability to generalize findings with certainty. Comparative evidence is lacking against some widely used treatments. Research provides context that long-term effects are not fully established, as the follow-up durations were limited across the primary evidence base.

Frequently Asked Questions (FAQ)

Common questions about Yohimbex (FAQ)


Q: What is the approved medical purpose for prescribing Yohimbex?

Regulatory documents note that the medication is not currently identified as having a formal FDA-approved use or indication.

However, the active ingredient was previously investigated in research contexts for its effect on conditions such as erectile dysfunction, and this research forms the basis of its use context.


Q: How is the active ingredient in Yohimbex different from the yohimbe found in herbal supplements?

Yohimbex contains the purified and standardized salt form, Yohimbine HCl.

This differs significantly from herbal or crude yohimbe supplements, which often contain variable and unregulated amounts of yohimbine and other compounds found in the yohimbe bark extract.


Q: Is it necessary to avoid alcohol completely while undergoing treatment with Yohimbex?

Official drug information indicates that ethanol (alcohol) is listed as an interaction that may increase the risk of certain side effects.

Clarification with a healthcare provider about any special instructions is typically necessary.


Q: What is the official stance on using Yohimbex for purposes other than the main treatment?

The use of any drug for a reason other than what is specified in its regulatory approval is generally considered off-label use.

Official drug labeling focuses solely on the approved use; clinical decisions regarding off-label use are governed by clinical practice guidelines rather than federal drug labeling.


Q: Can Yohimbex affect a person's sleep pattern or cause insomnia?

While insomnia itself may not be explicitly listed, regulatory data and research note side effects that are closely related to sleep disturbance.

These include reports of nervousness, restlessness, and excitation, which are consistent with the drug's stimulant properties.


Q: What should be done if an interaction with another medicine is suspected after taking Yohimbex?

Drug information resources emphasize that professional guidance is necessary if an interaction is suspected.

Consultation with a healthcare provider or pharmacist is described as the appropriate step to determine the relevance of any potential interaction and how to manage it.


Q: Can Yohimbex be used by individuals who have a history of seizures?

The official safety profile for the drug is consistent with a high-risk medication due to its effects on the nervous system.

As a result, serious adverse events like seizures are listed as a potential risk.


Q: Is there any research that has examined the use of Yohimbex in combination with other approved treatments?

Clinical research has investigated the active ingredient in combination with specific agents, such as L-arginine, within a controlled research context.

However, official information does not typically address its use in combination with common first-line approved pharmaceutical treatments.


Q: Are there official statements about why Yohimbex is only available by prescription?

The prescription-only status of Yohimbex is due to the drug's complex and high-risk safety profile.

The drug's regulatory classification reflects the need for medical supervision to mitigate the potential for serious adverse reactions, such as severe cardiovascular issues, hypertensive crisis, and seizures.


Q: Why is Yohimbex sometimes mistakenly associated with athletic performance enhancement?

The drug's classification as a stimulant and its documented effects on alertness and energy are reasons why it is sometimes discussed in the context of athletic use.

However, official medical literature cautions that conclusive evidence for athletic performance benefit is lacking.


Q: Do official materials clarify if Yohimbex is suitable for female patients?

Official materials clearly state the product is contraindicated (must not be used) during pregnancy and breastfeeding.

The general patient population for the medication, as noted in the product description, is the adult male patient group.


Q: Is a fast or irregular heartbeat a known but infrequent side effect of Yohimbex?

The safety profile lists tachycardia (a fast heartbeat) as a commonly reported side effect, meaning it is not considered infrequent.

More serious, irregular heart rhythms, called tachyarrhythmias, are listed separately as potential serious adverse reactions.


Q: How do official sources describe the efficacy of Yohimbex in clinical trials?

Official sources summarizing clinical trials for conditions like non-organic erectile dysfunction often describe the overall response.

They state that the drug was observed to be significantly more effective than placebo in terms of response rate, but the overall documented efficacy is typically described as modest.


Q: What are the physical symptoms that would warrant immediate medical attention after taking Yohimbex?

Official patient information describes symptoms that are typically presented to the emergency medical services, such as a very irregular or fast heartbeat, chest pain, or any sign of confusion or unusual behavior.

How should Yohimbex be stored and disposed of?

How to Store and Dispose of Yohimbex (Yohimbine HCl)

The official regulatory documentation outlines specific requirements for storing and disposing of this medicine to maintain its stability and ensure safety.

Storage Component Required Condition
Temperature Store at room temperature, generally not exceeding 30 C (86 F).
Environmental Control The container must be kept away from heat, moisture, and direct light; the product must not be frozen.
Container Security Keep the medicine in a closed container and out of the reach of children.

For disposal, the regulatory guidance states that outdated or no longer needed medicine must not be kept. When discarding the product, it must not be flushed down a toilet or poured down a drain; instead, consult a pharmacist or local waste disposal service for the proper procedure for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Yohimbex found in:

A-Z Index: